Skip to main content

Posts tagged with "Drug Development"

  • Business and Markets

    Virtual Biotech, Like It or Not

    We’ve all been hearing for a while about “virtual biotechs”. The term usually refers to a company with only a handful of employees and no real laboratory space of its own. All the work is contracted out. That means that what’s left back at the tiny headquarters (which in a couple of cases is as… Read More
  • Drug Development

    What’s the Ugliest Drug? Or The Ugliest Drug Candidate?

    I was having one of those “drug-like properties” discussions with colleagues the other day. Admittedly, if you’re not in drug discovery yourself, you probably don’t have that one very often, but even for us, you’d think that a lot of the issues would be pretty settled by now. Not so. While everyone broadly agrees that… Read More
  • Drug Assays

    Dealing with the Data

    So how do we deal with the piles of data? A reader sent along this question, and it’s worth thinking about. Drug research – even the preclinical kind – generates an awful lot of information. The other day, it was pointed out that one of our projects, if you expanded everything out, would be displayed… Read More
  • Academia (vs. Industry)

    Merck’s CALIBR Venture

    So the news is that Merck is now going to start its own nonprofit drug research institute in San Diego: CALIBR, the California Institute for Biomedical Research. It’ll be run by Peter Schultz of Scripps, and they’re planning to hire about 150 scientists (which is good news, anyway, since the biomedical employment picture out in… Read More
  • Drug Development

    Not Quite So Accelerated, Says PhRMA

    We’ve spent a lot of time here talking about provisional approval of drugs, most specifically Avastin (when its approval for metastatic breast cancer was pulled). But the idea isn’t to put drugs on the market that have to be taken back; it’s to get them out more quickly in case they actually work. There’s legislation… Read More
  • Drug Assays

    The Blackian Demon of Drug Discovery

    There’s an on-line appendix to that Nature Reviews Drug Discovery article that I’ve been writing about, and I don’t think that many people have read it yet. Jack Scannell, one of the authors, sent along a note about it, and he’s interested to see what the readership here makes of it. It gets to the… Read More
  • Drug Development

    The Brute Force Bias

    I wanted to return to that Nature Reviews Drug Discovery article I blogged about the other day. There’s one reason the authors advance for our problems that I thought was particularly well stated: what they call the “basic research/brute force” bias. The ‘basic research–brute force’ bias is the tendency to overestimate the a… Read More
  • Drug Assays

    Drug Discovery for Physicists

    There’s a good post over at the Curious Wavefunction on the differences between drug discovery and the more rigorous sciences. I particularly liked this line: The goal of many physicists was, and still is, to find three laws that account for at least 99% of the universe. But the situation in drug discovery is more… Read More
  • Drug Development

    Scaling Up a Strange Dinitro Compound (And Others)

    I wrote here about a very unusual dinitro compound that’s in the clinic in oncology. Now there’s a synthetic chemistry follow-up, in the form of a paper in Organic Process R&D. It’s safe to say that most process and scale-up chemists are never going to have to worry about making a gem-dinitroazetidine – or, for… Read More
  • Business and Markets

    The Terrifying Cost of a New Drug

    Matthew Herper at Forbes has a very interesting column, building on some data from Bernard Munos (whose work on drug development will be familiar to readers of this blog). What he and his colleague Scott DeCarlo have done is conceptually simple: they’ve gone back over the last 15 years of financial statements from a bunch… Read More